Mergers & Acquisitions ·
Elutia Inc. entered into an Asset Purchase Agreement with Cellution Biologics Inc. to sell its SimpliDerm human…
ELUTElutia Inc.
Elutia Inc. entered into an Asset Purchase Agreement with Cellution Biologics Inc. to sell its SimpliDerm human acellular dermal matrix business for up to $11 million. The transaction includes $8 million in cash at closing and up to $3 million in contingent technology transfer and commercial milestone payments. The divestiture is intended to focus the company's resources on its NXT-41x antibiotic-eluting biomatrix. Elutia Inc. develops and commercializes drug-eluting biomatrix products for medical device compatibility.